PANACEA BIOTEC LTD. - 531349 - Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2024
The Board of Directors in its meeting held on May 30, 2024 approved the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2024 PANACEA BIOTEC LTD. - 531349 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 30, 2024
We would like to inform that pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , the Board of Directors of the Company has, at its meeting held today, i.e. May 30, 2024, inter-alia, considered and approved the Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2024. The same was also reviewed by the Audit Committee in its meeting held on May 29, 2024. PANACEA BIOTEC LTD. - 531349 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Please find enclosed Secretarial Compliance report duly issued by R&D Company Secretaries, Practicing Company Secretaries for the financial year ended March 31, 2024 PANACEA BIOTEC LTD. - 531349 - Intimation Of Withdrawal Of Reclassification Application In Terms Of The Provisions Of Regulation 31A(8) Of Listing Regulations
We would like to inform you that an application vide letter dated September 06, 2023 along with side requisite documents submitted with stock exchanges for seeking reclassification of few members from promoter and promoter group has been withdrawn by the Company vide its letter dated May 23, 2024 PANACEA BIOTEC LTD. - 531349 - Board Meeting Intimation for Approving Standalone And Consolidated Audited Financial Results For Quarter And Financial Year Ended March 31, 2024
PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 ,inter alia, to consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31, 2024. With reference to our earlier announcement dated March 27, 2024 intimating the Closure of Trading Window pursuant to the Company''s Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the trading window of the Company shall remain closed for all Designated Persons of the Company till June 01, 2024. PANACEA BIOTEC LTD. - 531349 - Details Of Shares Dematerialised During April, 2024 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018
We would like to inform you that no share has been dematerialised during the month of April, 2024. A copy of the certificate obtained from the Company''s RTA viz. Skyline Financial Services Pvt. Ltd. regarding shares dematerialised as on April 30, 2024 is enclosed herewith. PANACEA BIOTEC LTD. - 531349 - Intimation Regarding Appointment Of Senior Management Personnel In The Company'S Material Subsidiary Viz. Panacea Biotec Pharma Limited
We would like to inform you that Mr. Rishi Prakash , Vice President - Business Development has been appointed as Senior Management Personnel of Panacea Biotec Pharma Ltd w.e.f. May 01, 2024. The disclosure pursuant to SEBI Circular dated July 13, 2023 is attached herewith. PANACEA BIOTEC LTD. - 531349 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyPANACEA BIOTEC LTD. 2CIN NO.L33117PB1984PLC022350 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 15.00 4Highest Credit Rating during the previous FY NotApplicable 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Vinod Goel Designation: Group CFO and Head Legal and Company Secretary EmailId: vinodgoel@panaceabiotec.com Name of the Chief Financial Officer: Devender Gupta Designation: Chief Financial Officer and Head IT EmailId: devendergupta@panaceabiotec.com Date: 30/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. PANACEA BIOTEC LTD. - 531349 - Intimation Regarding Resignation Of Senior Management Personnel Of The Company'S Material Subsidiary Viz. Panacea Biotec Pharma Limited ('PBPL')
We would like to inform you that Mr. Sanjay Kumar, Sr. General Manager - Quality (Pharma & Oncology) of the Company''s material subsidiary, Panacea Biotec Pharma Ltd. has tendered his resignation. In this regard, a copy of the resignation letter is attached herewith as Annexure -A PANACEA BIOTEC LTD. - 531349 - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended March 31, 2024
We are enclosing herewith the certified copy of certificate received from M/s R&D Company Secretaries, for the financial year ended March 31, 2024, confirming that all Letter of Confirmation(s) have been issued by the Company within the stipulated time from the date of lodgement for sub-division, consolidation, renewal, exchange or endorsement of calls/allotment of monies, change of name, as the case may be.